ヘルスケア分析試験サービス市場

出版:MarketsandMarkets

Healthcare Analytical Testing Services Market by Type (Method Development & Validation, Cell-based Assays, Stability Testing, Heavy Metal Testing, Thermal Analysis, Cleaning Validation), End User (Pharmaceutical Companies, CROs) – Global Forecast to 2026

出版 MarketsandMarkets
出版年月 2021年9月
ページ数 345
図表数 366
種別 英文調査報告書

レポート目次  お問合せ

ヘルスケア分析試験サービス市場 タイプ(メソッド開発と妥当性確認、セルベースのアッセイ、安定性試験、重金属試験、熱分析、洗浄バリデーション)、エンドユーザー(製薬会社、CRO)別

The healthcare analytical testing services market is projected to reach USD 9.8 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of 11.9%. Growth in the market is driven by the rising trend of outsourcing of analytical testing by pharmaceutical companies and medical device companies, an increasing number of clinical trials, and the rising acceptance of the QbD approach in pharma research and manufacturing.

“The batch-release testing segment is expected to grow at the highest rate, by type, in the healthcare analytical testing services market, in the forecast period.”
On the basis of type, the healthcare analytical testing services market is segmented into bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services.
In the forecast period, batch-release testing segment is expected to grow at the highest rate, by type. The high growth of this segment can be attributed to the utility of these services in ensuring that pharmaceutical products are compliant with regulations and meet specifications within the marketing authorization (MA) or Clinical Trial Dossier (CTD). Within the batch-release testing segment, the dissolution testing services segment holds the highest market share and is growing at the highest rate in the forecast period.

“In the bioanalytical testing services segment, cell-based assay services holds the highest share in the market in the forecast period.”
On the basis of type, the healthcare analytical testing services market is segmented into bioanalytical testing, physical characterization, method development & validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services.
The bioanalytical testing services segment holds the highest share during the forecast period. Within this segment, cell-based assay services holds the highest market share. This high market share can be attributed to the usage of cell-based assays in high-throughput screening, which has increased due to their ability to provide relevant in vivo biological information, consequently accelerating the process of drug discovery.

“The medical device companies segment is expected to grow at the highest rate, by end user, in the healthcare analytical testing services market, in the forecast period.”

In this report, the healthcare analytical testing services market has been segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and contract research organizations (CROs), by end user. The medical device companies segment is expected to grow at the highest rate in the market in the forecast period. The high growth rate of the segment maybe attributed to increasing demand by OEMs for more services and expertise, evolving regulatory scenarios, technological advancements in medical devices, and the adoption of point-of-care (POC) testing driving the demand for healthcare analytical testing services among medical device companies.

“APAC is expected to grow at the highest rate in the healthcare analytical testing services market, by region, in the forecast period”
The healthcare analytical testing services market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is expected to grow at the highest rate, by region, in the forecast period. This high growth rate can be attributed to significant growth opportunities in emerging Asian countries and lower their production costs by shifting manufacturing and drug R&D operations to the region, making this region a major destination for drug discovery and development. Moreover, the large number of qualified researchers and the low cost of operations in APAC countries, such as India and China, have supported this trend.

A breakdown of the primary participants for the healthcare analytical testing services market referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–35%, and Tier 3–25%
• By Designation: C-level–45%, Director Level–35%, and Others–20%
• By Region: North America–45%, Europe–25%, Asia Pacific–15%, Latin America – 10%, Middle East & Africa – 5%

The prominent players in the global healthcare analytical testing services market are Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), PPD, Inc. (US), Element Materials Technology (UK), Thermo Fisher Scientific (US), Pace Analytical Services, LLC. (US), Intertek Group LLC. (UK), Merck KGaA (Germany), Danaher Corporation (US), Source BioScience (UK), Almac Group (UK), ICON plc (Ireland), Frontage Laboratories, Inc. (US), STERIS plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health (US), Medpace Holdings, Inc. (US), Cinven (LGC Limited) (UK), Anacura (Belgium), Impact Analytical (US), & CD BioSciences (US).

Research Coverage
The report analyzes the market for various healthcare analytical testing services and their adoption pattern. It aims at estimating the market size and future growth potential of the healthcare analytical testing services and different segments such as by type, end user and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, services, and recent developments.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the service portfolios offered by the top players in the global healthcare analytical testing services market.
• Service Development/Innovation: Detailed insights on the upcoming trend, and service launches in the global healthcare analytical testing services market.
• Market Development: Comprehensive information on the lucrative emerging regions by type, end users, and region.
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global healthcare analytical testing services market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and services of leading players in the global healthcare analytical testing services market.


目次

1 INTRODUCTION 45
1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.2.1 INCLUSIONS AND EXCLUSIONS 45
1.3 MARKET SCOPE 46
1.3.1 MARKETS COVERED 46
FIGURE 1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SEGMENTATION 46
FIGURE 2 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION 47
1.3.2 YEARS CONSIDERED FOR THE STUDY 47
1.4 CURRENCY 47
1.5 LIMITATIONS 48
1.6 STAKEHOLDERS 48
1.7 SUMMARY OF CHANGES 49
2 RESEARCH METHODOLOGY 50
2.1 RESEARCH DATA 50
FIGURE 3 RESEARCH DESIGN 50
2.1.1 SECONDARY DATA 50
2.1.1.1 Key data from secondary sources 51
2.1.2 SECONDARY RESEARCH 51
2.1.3 PRIMARY DATA 52
FIGURE 4 PRIMARY SOURCES 52
2.1.3.1 Key data from primary sources 53
2.1.3.2 Insights from primary experts 53
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 54
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 54
2.2 MARKET SIZE ESTIMATION: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 55
FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 55
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION 56
FIGURE 9 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2021–2026) 57
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 58
FIGURE 11 TOP-DOWN APPROACH 58
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 59
FIGURE 12 DATA TRIANGULATION METHODOLOGY 59
2.4 MARKET SHARE ESTIMATION 60
2.5 ASSUMPTIONS FOR THE STUDY 60
2.6 LIMITATIONS 60
2.6.1 METHODOLOGY-RELATED LIMITATIONS 61
2.6.2 SCOPE-RELATED LIMITATIONS 61
2.7 RISK ASSESSMENT 61
TABLE 1 RISK ASSESSMENT: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 61
3 EXECUTIVE SUMMARY 62
FIGURE 13 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 62
FIGURE 14 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 63
FIGURE 15 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 63
FIGURE 16 GEOGRAPHIC SNAPSHOT OF THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 64
4 PREMIUM INSIGHTS 65
4.1 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET OVERVIEW 65
FIGURE 17 GROWTH IN THE MARKET DRIVEN BY THE GROWING DEVELOPMENT OF PHARMACEUTICALS 65
4.2 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE 66
FIGURE 18 BIOANALYTICAL TESTING SERVICES COMMANDED THE LARGEST SHARE IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, IN 2020 66
4.3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC MIX 67
FIGURE 19 CHINA TO WITNESS THE HIGHEST GROWTH IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET DURING THE FORECAST PERIOD 67
4.4 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: REGIONAL MIX (2020–2025) 68
FIGURE 20 NORTH AMERICA TO DOMINATE THE MARKET IN THE FORECAST PERIOD 68
5 MARKET OVERVIEW 69
5.1 INTRODUCTION 69
5.2 MARKET DYNAMICS 69
FIGURE 21 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 69
5.2.1 DRIVERS 70
5.2.1.1 Focus on analytical testing of biologics & biosimilars 70
TABLE 2 PATENT EXPIRY OF BEST-SELLING BIOLOGICS 70
5.2.1.2 Increasing outsourcing of analytical testing by pharmaceutical companies and medical device companies 71
5.2.1.3 Increasing number of clinical trials 71
FIGURE 22 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2002–2021) 71
5.2.1.4 Rising acceptance of the quality-by-design approach in pharma research and manufacturing 72
5.2.2 RESTRAINTS 72
5.2.2.1 Shortage of skilled professionals 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Specialized testing 73
5.2.3.2 Emerging markets 73
5.2.4 CHALLENGES 74
5.2.4.1 Specific requirements of innovative formulations and medical devices 74
5.2.4.2 Need to improve the sensitivity of bioanalytical methods 74
5.2.4.3 Rising costs of bioanalytical testing methods and technology 75
5.3 COVID-19 IMPACT ANALYSIS 75
5.3.1 COVID-19 HEALTH ASSESSMENT 75
5.4 COVID-19 ECONOMIC ASSESSMENT 76
5.5 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 76
FIGURE 23 CRITERIA IMPACTING THE GLOBAL ECONOMY 76
5.6 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN
THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 77
5.7 ECOSYSTEM/MARKET MAP 78
TABLE 3 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: ECOSYSTEM 78
5.8 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS 79
FIGURE 24 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS 79
5.9 PATENT ANALYSIS: BIOANALYTICAL TESTING 80
FIGURE 25 MAJOR PATENTS FOR BIOANALYTICAL TESTING 80
5.10 CASE STUDY ANALYSIS 80
5.10.1 CASE STUDY 1: WELLSTAT THERAPEUTICS & ALMAC GROUP 80
5.10.2 CASE STUDY 2: METHOD DEVELOPMENT CASE STUDY 80
5.11 TECHNOLOGICAL ANALYSIS IN HEALTHCARE ANALYTICAL TESTING SERVICES 81
5.11.1 LIMS (LABORATORY INFORMATION SYSTEMS) PLATFORMS 81
5.12 REGULATORY LANDSCAPE 81
TABLE 4 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS 81
TABLE 5 DEVELOPMENT OF GLP ACROSS COUNTRIES 83
TABLE 6 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES 83
TABLE 7 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES 84
5.13 PORTER’S FIVE FORCES ANALYSIS 84
TABLE 8 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 84
5.13.1 THREAT FROM NEW ENTRANTS 85
5.13.1.1 Highly fragmented market despite ongoing consolidation 85
5.13.2 BARGAINING POWER OF SUPPLIERS 85
5.13.2.1 Technical expertise of specific market players 85
5.13.3 INTENSITY OF COMPETITIVE RIVALRY 85
5.13.3.1 Large number of healthcare analytical testing services companies at the regional level 85
5.13.4 BARGAINING POWER OF BUYERS 85
5.13.4.1 Rising pressure on pharmaceutical companies to increase ROI, and R&D productivity 86
5.13.5 THREAT FROM SUBSTITUTES 86
5.13.5.1 Rising preference by pharmaceutical companies for outsourcing drug development 86
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE 87
6.1 INTRODUCTION 88
TABLE 9 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 88
6.2 BIOANALYTICAL TESTING SERVICES 88
TABLE 10 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 89
TABLE 11 BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 89
6.2.1 CELL-BASED ASSAY SERVICES 90
6.2.1.1 The growing pipeline of biologics drives the growth of cell-based assays 90
TABLE 12 CELL-BASED ASSAY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 91
6.2.2 VIROLOGY TESTING SERVICES 91
6.2.2.1 Regulatory requirements drive the growth of virology testing in the drug development process 91
TABLE 13 VIROLOGY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 92
6.2.3 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES 92
6.2.3.1 The rising need to ensure the clinical safety of biopharmaceuticals drives the growth of this segment 92
TABLE 14 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
6.2.4 BIOMARKER TESTING SERVICES 94
6.2.4.1 The need to improve the monitoring of drug activity and therapeutic response will drive the biomarker testing services market 94
TABLE 15 BIOMARKER TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 95
6.2.5 PHARMACOKINETIC TESTING SERVICES 95
6.2.5.1 The increasing number of clinical and preclinical studies promote the growth of this segment 95
TABLE 16 PHARMACOKINETIC TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 96
6.2.6 OTHER BIOANALYTICAL TESTING SERVICES 96
TABLE 17 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 97
6.3 PHYSICAL CHARACTERIZATION SERVICES 97
TABLE 18 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 98
TABLE 19 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 98
6.3.1 LASER PARTICLE SIZE ANALYSIS SERVICES 99
6.3.1.1 The need to maintain particle size, uniformity, and consistency in pharmaceutical drug products is driving market growth 99
TABLE 20 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 99
6.3.2 THERMAL ANALYSIS SERVICES 100
6.3.2.1 The rising usage of solid dispersions and other polymeric dosage forms will drive the growth of this market 100
TABLE 21 THERMAL ANALYSIS SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 100
6.3.3 IMAGE ANALYSIS SERVICES 101
6.3.3.1 Growing complexity of biological structures to support the growth of this market 101
TABLE 22 IMAGE ANALYSIS SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 102
6.3.4 SURFACE AREA ANALYSIS SERVICES 102
6.3.4.1 Growing application of surface analysis in streamlining the drug development process to drive the growth of the segment 102
TABLE 23 SURFACE AREA ANALYSIS SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 103
6.3.5 OTHER PHYSICAL CHARACTERIZATION SERVICES 104
TABLE 24 OTHER PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 104
6.4 METHOD DEVELOPMENT & VALIDATION SERVICES 105
TABLE 25 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 26 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 106
6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES 106
6.4.1.1 Extractable studies are required to facilitate the analysis of leachables and control leachables in final drug products 106
TABLE 27 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 107
6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES 107
6.4.2.1 Regulatory requirements to control process impurities to drive
the growth of this segment in the drug development process 107
TABLE 28 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
6.4.3 STABILITY-INDICATING METHOD VALIDATION SERVICES 108
6.4.3.1 Need to guarantee safety, efficacy, and quality of therapeutic product to drive the growth of this market 108
TABLE 29 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 109
6.4.4 CLEANING VALIDATION SERVICES 109
6.4.4.1 Cleaning validation processes are necessary to evaluate cleaning practices and ensure complete decontamination 109
TABLE 30 CLEANING VALIDATION SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 110
6.4.5 ANALYTICAL STANDARD CHARACTERIZATION SERVICES 110
6.4.5.1 Analytical standard characterization plays a vital role in drug development 110
TABLE 31 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 111
6.4.6 TECHNICAL CONSULTING SERVICES 111
6.4.6.1 Technical consulting services assist pharmaceutical and biopharmaceutical companies in meeting regulatory requirements 111
TABLE 32 TECHNICAL CONSULTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 112
6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES 112
TABLE 33 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 113
6.5 RAW MATERIAL TESTING SERVICES 113
TABLE 34 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 114
TABLE 35 RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 114
6.5.1 COMPLETE COMPENDIAL TESTING SERVICES 115
6.5.1.1 Complete compendial testing detects the efficacy and safety of therapeutic products 115
TABLE 36 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 115
6.5.2 CONTAINER TESTING SERVICES 116
6.5.2.1 Container closure integrity testing helps optimize sealing, evaluate temperature impact, and replace sterility tests for product stability batches 116
TABLE 37 CONTAINER TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 116
6.5.3 HEAVY METAL TESTING SERVICES 117
6.5.3.1 Heavy metals in finished pharmaceutical products and raw materials are tested to ensure the quality of the product & patient safety 117
TABLE 38 HEAVY METAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 117
6.5.4 KARL FISCHER ANALYSIS SERVICES 118
6.5.4.1 Need to check for water content in pharmaceutical products to support the market growth 118
TABLE 39 KARL FISCHER ANALYSIS TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 118
6.5.5 WET CHEMISTRY ANALYSIS SERVICES 119
6.5.5.1 Wet chemistry analysis provides qualitative and quantitative data on elements in samples 119
TABLE 40 WET CHEMISTRY ANALYSIS TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 119
6.5.6 OTHER RAW MATERIAL TESTING SERVICES 120
TABLE 41 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 120
6.6 BATCH-RELEASE TESTING SERVICES 120
TABLE 42 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 121
TABLE 43 BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 121
6.6.1 DISSOLUTION TESTING SERVICES 122
6.6.1.1 Dissolution testing plays a vital role in the pharmaceutical industry, from R&D to the control and evaluation of drug quality 122
TABLE 44 DISSOLUTION TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 123
6.6.2 ELEMENTAL IMPURITY TESTING SERVICES 123
6.6.2.1 The need to detect organic and inorganic impurities in active pharmaceuticals and ingredients drives demand for elemental impurity testing 123
TABLE 45 ELEMENTAL PURITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
6.6.3 DISINTEGRATION TESTING SERVICES 125
6.6.3.1 Disintegration testing is performed to ensure batch-to-batch consistency of pharmaceutical dosage forms 125
TABLE 46 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA 125
TABLE 47 DISINTEGRATION TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
6.6.4 HARDNESS TESTING SERVICES 126
6.6.4.1 Hardness testing helps determine resistance to mechanical shocks and tablet strength 126
TABLE 48 HARDNESS TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 127
6.6.5 FRIABILITY TESTING SERVICES 127
6.6.5.1 Friability testing measures the resistance of tablets and granules to abrasion or fracture 127
TABLE 49 FRIABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
6.6.6 OTHER BATCH-RELEASE TESTING SERVICES 129
TABLE 50 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 129
6.7 STABILITY TESTING SERVICES 129
TABLE 51 STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 130
TABLE 52 STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 130
6.7.1 DRUG SUBSTANCE STABILITY TESTING SERVICES 131
6.7.1.1 Substance stability testing is a necessary step in the drug approval process 131
TABLE 53 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 131
6.7.2 FORMULATION EVALUATION STABILITY TESTING SERVICES 132
6.7.2.1 These tests provide data on expiry and storage conditions required 132
TABLE 54 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 132
6.7.3 ACCELERATED STABILITY TESTING SERVICES 133
6.7.3.1 Accelerated stability testing determines the shelf-life of a pharmaceutical product by measuring degradation caused by stress 133
TABLE 55 ACCELERATED STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 133
6.7.4 PHOTOSTABILITY TESTING SERVICES 134
6.7.4.1 Photostability tests establish the effect of light exposure on products 134
TABLE 56 PHOTOSTABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 135
6.7.5 COMPARATIVE STABILITY TESTING SERVICES 135
6.7.5.1 Comparator studies and blind comparator stability testing are performed to check if a pharmaceutical product is equivalent or superior to the marketed drug product in the same therapeutic class 135
TABLE 57 COMPARATIVE STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 136
6.7.6 OTHER STABILITY TESTING SERVICES 136
TABLE 58 OTHER STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 137
6.8 MICROBIAL TESTING SERVICES 137
TABLE 59 MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 60 MICROBIAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 138
6.8.1 MICROBIAL LIMIT TESTING SERVICES 139
6.8.1.1 Microbial limit testing determines whether a product complies with compendial specifications for microbial quality 139
TABLE 61 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING 139
TABLE 62 MICROBIAL LIMIT TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 140
6.8.2 STERILITY TESTING SERVICES 140
6.8.2.1 Sterility testing of a pharmaceutical product is required during the sterilization validation process and routine release testing to enhance product quality 140
TABLE 63 STERILITY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 141
6.8.3 ENDOTOXIN TESTING SERVICES 141
6.8.3.1 LAL tests are used to test for the presence of endotoxins in compliance with regulatory requirements 141
TABLE 64 ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 142
6.8.4 PRESERVATIVE EFFICACY TESTING SERVICES 142
6.8.4.1 Preservative efficacy testing determines the type and minimum effective concentration of preservatives required for a formulation 142
TABLE 65 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 143
6.8.5 WATER TESTING SERVICES 143
6.8.5.1 Need to ensure water quality creates demand for water testing 143
TABLE 66 STANDARDIZED LIMITS FOR WATER TESTING 144
TABLE 67 WATER TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 144
6.8.6 OTHER MICROBIAL TESTING SERVICES 145
TABLE 68 OTHER MICROBIAL TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 145
6.9 ENVIRONMENTAL MONITORING SERVICES 146
TABLE 69 ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 146
TABLE 70 ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 147
6.9.1 AIR TESTING SERVICES 147
6.9.1.1 Air contamination can prove highly harmful to product quality, which necessitates regular testing 147
TABLE 71 PURITY CLASSES FOR PARTICLES, WATER, AND OIL IN COMPRESSED AIR 148
TABLE 72 AIR TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 149
6.9.2 WATER TESTING SERVICES 149
6.9.2.1 Need to minimize water contamination supports the demand for water testing 149
TABLE 73 STANDARDS FOR WASTEWATER QUALITY 150
TABLE 74 WATER TESTING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 150
6.9.3 OTHER ENVIRONMENTAL MONITORING SERVICES 151
TABLE 75 OTHER ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 151
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER 152
7.1 INTRODUCTION 153
TABLE 76 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 153
7.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 153
7.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES DOMINATE
THE HEALTHCARE TESTING SERVICES MARKET 153
FIGURE 26 R&D SPENDING OF PHRMA MEMBER-COMPANIES, 1995–2019 154
TABLE 77 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 155
7.3 MEDICAL DEVICE COMPANIES 155
7.3.1 R&D SPENDING ON MEDICAL DEVICE DEVELOPMENT HAS INCREASED IN RECENT YEARS 155
TABLE 78 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 156
7.4 CONTRACT RESEARCH ORGANIZATIONS 157
7.4.1 INCREASING FOCUS ON OUTSOURCING WILL SUPPORT MARKET GROWTH 157
TABLE 79 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET FOR CROS,
BY COUNTRY, 2019–2026 (USD MILLION) 157
8 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION 158
8.1 INTRODUCTION 159
FIGURE 27 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 159
TABLE 80 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 159
8.2 NORTH AMERICA 160
FIGURE 28 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA (2019) 160
FIGURE 29 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SNAPSHOT 161
TABLE 81 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 162
TABLE 82 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 83 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 84 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 85 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 164
TABLE 86 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 164
TABLE 87 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 165
TABLE 88 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 89 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 166
TABLE 90 NORTH AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 166
TABLE 91 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 166
8.2.1 US 167
8.2.1.1 The US dominated the North American healthcare analytical testing services market in 2020 167
FIGURE 30 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019) 167
TABLE 92 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 168
TABLE 93 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 168
TABLE 94 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 169
TABLE 95 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 96 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 170
TABLE 97 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 170
TABLE 98 US: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 171
TABLE 99 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 171
TABLE 100 US: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 171
TABLE 101 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 172
8.2.2 CANADA 172
8.2.2.1 Increasing number of clinical trials to support the growth of the market 172
TABLE 102 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2020) 173
TABLE 103 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 104 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 174
TABLE 105 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 174
TABLE 106 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 175
TABLE 107 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 175
TABLE 108 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 176
TABLE 109 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 176
TABLE 110 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 177
TABLE 111 CANADA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 112 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 177
8.3 EUROPE 178
TABLE 113 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 178
TABLE 114 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 115 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 179
TABLE 116 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 180
TABLE 117 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 180
TABLE 118 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 181
TABLE 119 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 181
TABLE 120 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 182
TABLE 121 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 182
TABLE 122 EUROPE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 123 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 183
8.3.1 GERMANY 183
8.3.1.1 Growing biopharmaceutical sector in the country driving market growth 183
TABLE 124 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 184
TABLE 125 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 184
TABLE 126 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 127 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 128 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 186
TABLE 129 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 186
TABLE 130 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 187
TABLE 131 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 187
TABLE 132 GERMANY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 187
TABLE 133 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 188
8.3.2 UK 188
8.3.2.1 Increasing partnerships between the government, the NHS, and the pharmaceutical & life sciences sector to support the market growth 188
TABLE 134 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 189
TABLE 135 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 189
TABLE 136 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 190
TABLE 137 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 190
TABLE 138 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 139 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 140 UK: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 192
TABLE 141 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 192
TABLE 142 UK: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 192
TABLE 143 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 193
8.3.3 FRANCE 193
8.3.3.1 Growing pharmaceutical R&D expenditure in the country driving market growth 193
TABLE 144 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 194
TABLE 145 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 194
TABLE 146 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 195
TABLE 147 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 195
TABLE 148 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 196
TABLE 149 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 196
TABLE 150 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 197
TABLE 151 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 197
TABLE 152 FRANCE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 197
TABLE 153 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 198
8.3.4 ITALY 198
8.3.4.1 A growing number of clinical trials to support the market in Italy 198
TABLE 154 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 155 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 199
TABLE 156 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 199
TABLE 157 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 200
TABLE 158 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 200
TABLE 159 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 201
TABLE 160 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 201
TABLE 161 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 202
TABLE 162 ITALY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 202
TABLE 163 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 202
8.3.5 SWITZERLAND 203
8.3.5.1 Large and growing pharma production volume will drive demand for analytical testing services 203
TABLE 164 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 203
TABLE 165 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 204
TABLE 166 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 204
TABLE 167 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 205
TABLE 168 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 205
TABLE 169 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 206
TABLE 170 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 206
TABLE 171 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 207
TABLE 172 SWITZERLAND: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 173 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 207
8.3.6 SPAIN 208
8.3.6.1 Rising R&D expenditure to boost the growth of analytical testing services 208
TABLE 174 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 208
TABLE 175 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 209
TABLE 176 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 209
TABLE 177 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 210
TABLE 178 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 210
TABLE 179 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 211
TABLE 180 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 211
TABLE 181 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 212
TABLE 182 SPAIN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 212
TABLE 183 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 212
8.3.7 REST OF EUROPE 213
TABLE 184 ROE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 213
TABLE 185 ROE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 186 ROE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 214
TABLE 187 ROE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 215
TABLE 188 ROE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 215
TABLE 189 ROE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 216
TABLE 190 ROE: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 216
TABLE 191 ROE: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 217
TABLE 192 ROE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 217
TABLE 193 ROE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 217
8.4 ASIA PACIFIC 218
FIGURE 31 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SNAPSHOT 218
TABLE 194 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 219
TABLE 195 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 219
TABLE 196 APAC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 220
TABLE 197 APAC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 220
TABLE 198 APAC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 221
TABLE 199 APAC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 221
TABLE 200 APAC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 222
TABLE 201 APAC: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 222
TABLE 202 APAC: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 223
TABLE 203 APAC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 223
TABLE 204 APAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 223
8.4.1 CHINA 224
8.4.1.1 Large pharmaceutical R&D footprint in China will drive market growth 224
TABLE 205 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 224
TABLE 206 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 225
TABLE 207 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 225
TABLE 208 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 226
TABLE 209 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 226
TABLE 210 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 227
TABLE 211 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 227
TABLE 212 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 228
TABLE 213 CHINA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 228
TABLE 214 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 228
8.4.2 JAPAN 229
8.4.2.1 Japan is notable for demonstrating strong support for R&D 229
TABLE 215 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 229
TABLE 216 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 230
TABLE 217 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 230
TABLE 218 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 231
TABLE 219 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 231
TABLE 220 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 232
TABLE 221 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 232
TABLE 222 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 233
TABLE 223 JAPAN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 233
TABLE 224 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 233
8.4.3 INDIA 234
8.4.3.1 India to offer lucrative growth opportunities for market players 234
TABLE 225 INCREASE IN THE R&D EXPENDITURE OF TOP FIVE INDIAN PHARMACEUTICAL COMPANIES, 2010 VS. 2018 (USD MILLION) 234
TABLE 226 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 235
TABLE 227 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 235
TABLE 228 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 236
TABLE 229 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 236
TABLE 230 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 237
TABLE 231 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 237
TABLE 232 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 238
TABLE 233 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 238
TABLE 234 INDIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 238
TABLE 235 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 239
8.4.4 AUSTRALIA 239
8.4.4.1 Australia is a favorable location for drug discovery due to the large number of research institutes in the country 239
TABLE 236 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 239
TABLE 237 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 240
TABLE 238 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 240
TABLE 239 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 241
TABLE 240 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 241
TABLE 241 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 242
TABLE 242 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 242
TABLE 243 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 243
TABLE 244 AUSTRALIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 243
TABLE 245 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 243
8.4.5 SOUTH KOREA 244
8.4.5.1 Growth in clinical trial activity to support the market in South Korea 244
TABLE 246 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 244
TABLE 247 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 245
TABLE 248 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 245
TABLE 249 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 246
TABLE 250 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 246
TABLE 251 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 247
TABLE 252 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 247
TABLE 253 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 248
TABLE 254 SOUTH KOREA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 248
TABLE 255 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 248
8.4.6 REST OF ASIA PACIFIC 249
TABLE 256 ROAPAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 249
TABLE 257 ROAPAC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 250
TABLE 258 ROAPAC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 250
TABLE 259 ROAPAC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 251
TABLE 260 ROAPAC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 251
TABLE 261 ROAPAC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 252
TABLE 262 ROAPAC: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 252
TABLE 263 ROAPAC: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 253
TABLE 264 ROAPAC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 253
TABLE 265 ROAPAC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 253
8.5 LATIN AMERICA 254
8.5.1 GROWING R&D EXPENDITURE TO DRIVE MARKET GROWTH 254
TABLE 266 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 254
TABLE 267 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 255
TABLE 268 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 255
TABLE 269 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 256
TABLE 270 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 256
TABLE 271 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 257
TABLE 272 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 257
TABLE 273 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 258
TABLE 274 LATIN AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 258
TABLE 275 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION) 258
8.6 MIDDLE EAST & AFRICA 259
8.6.1 MIDDLE EASTERN COUNTRIES ARE BECOMING ATTRACTIVE DESTINATIONS FOR PHARMA & MEDICAL DEVICE MANUFACTURERS 259
TABLE 276 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 259
TABLE 277 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 260
TABLE 278 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 260
TABLE 279 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 261
TABLE 280 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 261
TABLE 281 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION) 262
TABLE 282 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 262
TABLE 283 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 263
TABLE 284 MIDDLE EAST & AFRICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 263
TABLE 285 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 263
9 COMPETITIVE LANDSCAPE 264
9.1 INTRODUCTION 264
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 264
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 265
9.3 REVENUE SHARE ANALYSIS 266
9.3.1 REVENUE ANALYSIS FOR KEY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 266
FIGURE 32 REVENUE ANALYSIS FOR KEY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET IN THE PAST FIVE YEARS 266
9.4 MARKET SHARE ANALYSIS 267
9.4.1 MARKET SHARE ANALYSIS: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 267
FIGURE 33 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SHARE,
BY KEY PLAYER, 2020 267
TABLE 286 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DEGREE OF COMPETITION 268
9.5 COMPANY EVALUATION QUADRANT 268
9.5.1 COMPANY EVALUATION QUADRANT: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET 268
9.5.1.1 Stars 269
9.5.1.2 Pervasive players 269
9.5.1.3 Emerging leaders 269
9.5.1.4 Participants 269
FIGURE 34 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2020 270
9.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020) 271
9.6.1 PROGRESSIVE COMPANIES 271
9.6.2 DYNAMIC COMPANIES 271
9.6.3 STARTING BLOCKS 271
9.6.4 RESPONSIVE COMPANIES 271
FIGURE 35 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: SME/START-UP COMPANY EVALUATION MATRIX, 2020 272
9.7 COMPETITIVE BENCHMARKING 273
9.7.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES) 273
FIGURE 36 COMPANY SERVICE FOOTPRINT (20 COMPANIES) 274
TABLE 287 COMPANY END-USER FOOTPRINT (20 COMPANIES) 275
TABLE 288 COMPANY REGION FOOTPRINT (20 COMPANIES) 276
FIGURE 37 GEOGRAPHICAL ASSESSMENT OF THE KEY PLAYERS IN THE HEALTHCARE ANALYTICAL TESTING SERVICES MARKET (2020) 277
9.8 COMPETITIVE SITUATIONS AND TRENDS 277
9.8.1 SERVICE LAUNCHES & APPROVALS 277
TABLE 289 SERVICE LAUNCHES (2018–AUGUST 2021) 277
9.8.2 DEALS 278
TABLE 290 DEALS (2018–AUGUST 2021) 278
TABLE 291 OTHER DEVELOPMENTS (2018–AUGUST 2021) 279
10 COMPANY PROFILES 280
10.1 KEY PLAYERS 280
(Business Overview, Products/Solutions Offered, Recent Developments, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)*
10.1.1 EUROFINS SCIENTIFIC 280
TABLE 292 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 280
FIGURE 38 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020) 281
10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS 284
TABLE 293 LABCORP: BUSINESS OVERVIEW 284
FIGURE 39 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2020) 285
10.1.3 SGS 287
TABLE 294 SGS S.A.: BUSINESS OVERVIEW 287
FIGURE 40 SGS: COMPANY SNAPSHOT (2020) 288
10.1.4 CHARLES RIVER LABORATORIES 291
TABLE 295 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 291
FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020) 292
10.1.5 WUXI APPTEC 296
TABLE 296 WUXI APPTEC CO. LTD: BUSINESS OVERVIEW 296
FIGURE 42 WUXI APPTEC: COMPANY SNAPSHOT (2020) 297
10.1.6 PPD 300
TABLE 297 PPD: BUSINESS OVERVIEW 300
FIGURE 43 PPD: COMPANY SNAPSHOT (2020) 301
10.1.7 ELEMENT MATERIALS TECHNOLOGY 303
TABLE 298 ELEMENT MATERIALS TECHNOLOGY: BUSINESS OVERVIEW 303
10.1.8 THERMO FISHER SCIENTIFIC 305
TABLE 299 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 305
FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT: (2020) 306
10.1.9 PACE ANALYTICAL SERVICES 308
TABLE 300 PACE ANALYTICAL SERVICES: BUSINESS OVERVIEW 308
10.1.10 INTERTEK GROUP 311
TABLE 301 INTERTEK GROUP PLC: BUSINESS OVERVIEW 311
FIGURE 45 INTERTEK: COMPANY SNAPSHOT (2020) 312
10.1.11 MERCK KGAA 316
TABLE 302 MERCK KGAA: BUSINESS OVERVIEW 316
FIGURE 46 MERCK: COMPANY SNAPSHOT (2020) 317
10.1.12 DANAHER CORPORATION 319
TABLE 303 DANAHER CORPORATION: BUSINESS OVERVIEW 319
FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 320
10.1.13 SOURCE BIOSCIENCE 322
TABLE 304 SOURCE BIOSCIENCE: BUSINESS OVERVIEW 322
10.1.14 ALMAC GROUP 323
TABLE 305 ALMAC GROUP: BUSINESS OVERVIEW 323
10.1.15 ICON 325
TABLE 306 ICON: BUSINESS OVERVIEW 325
FIGURE 48 ICON: COMPANY SNAPSHOT (2020) 325
10.1.16 ALS LIFE SCIENCES 328
TABLE 307 ALS LIFE SCIENCES: BUSINESS OVERVIEW 328
FIGURE 49 ALS LIFE SCIENCES: COMPANY SNAPSHOT (2020) 329
10.1.17 FRONTAGE LABORATORIES 331
TABLE 308 FRONTAGE LABORATORIES: BUSINESS OVERVIEW 331
FIGURE 50 FRONTAGE LABORATORIES: COMPANY SNAPSHOT (2020) 332
10.1.18 STERIS 335
TABLE 309 STERIS: BUSINESS OVERVIEW 335
FIGURE 51 STERIS: COMPANY SNAPSHOT (2021) 336
10.1.19 SARTORIUS AG 338
TABLE 310 SARTORIUS AG: BUSINESS OVERVIEW 338
FIGURE 52 SARTORIUS: COMPANY SNAPSHOT (2020) 339
10.2 OTHER EMERGING PLAYERS 341
10.2.1 SYNEOS HEALTH 341
TABLE 311 SYNEOS HEALTH: BUSINESS OVERVIEW 341
10.2.2 MEDPACE HOLDINGS 342
TABLE 312 MEDPACE HOLDINGS: BUSINESS OVERVIEW 342
10.2.3 LGC LIMITED (CINVEN) 343
TABLE 313 LGC LIMITED: BUSINESS OVERVIEW 343
10.2.4 ANACURA 345
TABLE 314 ANACURA: BUSINESS OVERVIEW 345
10.2.5 IMPACT ANALYTICAL 347
10.2.6 CD BIOSCIENCES 347
*Business Overview, Products/Solutions Offered, Recent Developments, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.
11 APPENDIX 348
11.1 DISCUSSION GUIDE 348
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 354
11.3 AVAILABLE CUSTOMIZATIONS 356
11.4 RELATED REPORTS 356
11.5 AUTHOR DETAILS 357


お問合せフォーム

    ※レポートのタイトルは自動で入ります。

    お名前(必須)

    会社名(必須)

    部署名

    メールアドレス(必須)

    電話番号

    当ウェブサイトを知った経由を教えてください。

    お問合せ区分(必須)

    お問合せ内容(必須)

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com